Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as Single Therapy or in Combination With Enoxaparin in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, a Phase III Study.

Trial Profile

Taxotere-Enoxaparin-(ENOXA)-Study: 1st-Line Docetaxel-Platin Chemotherapy as Single Therapy or in Combination With Enoxaparin in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer, a Phase III Study.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2011

At a glance

  • Drugs Enoxaparin sodium (Primary) ; Carboplatin; Cisplatin; Docetaxel
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Acronyms ENOXA-NSCLC
  • Most Recent Events

    • 10 Nov 2011 Additional lead trial center identified as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Planned end date changed from 1 Mar 2012 to 1 Feb 2011 as reported by ClinicalTrials.gov.
    • 24 Feb 2011 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top